SCHEMBL2704262

SCHEMBL2704262

CC(=O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 6/20 0.85
AURKB Q96GD4 4/20 0.85
GABRA1 P14867 3/20 0.85
PLK1 P53350 3/20 0.85
PLK4 O00444 2/20 0.85
PDPK1 O15530 2/20 0.85
ABL1 P00519 2/20 0.85
EGFR P00533 2/20 0.85
LCK P06239 2/20 0.85
HCK P08631 2/20 0.85
ROS1 P08922 2/20 0.85
FGFR1 P11362 2/20 0.85
SRC P12931 2/20 0.85
FER P16591 2/20 0.85
FLT1 P17948 2/20 0.85
CSNK2A2 P19784 2/20 0.85
FGFR3 P22607 2/20 0.85
EPHA2 P29317 2/20 0.85
GRK5 P34947 2/20 0.85
KDR P35968 2/20 0.85

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10239212 0.93 AURKA (0.77) AURKAAURKBGABRA1PLK1PLK4
SCHEMBL16602406 0.93 AURKA (0.88) AURKAAURKBGABRA1PLK1PLK4
Mln-8054 SCHEMBL621589 0.92 AURKA (1.00) AURKAAURKBGABRA1PLK1PLK4
Mln-8054 SCHEMBL29372555 0.92 AURKA (1.00) AURKAAURKBGABRA1PLK1PLK4
Mln-8054 SCHEMBL29720492 0.92 AURKA (1.00) AURKAAURKBGABRA1PLK1PLK4
SCHEMBL2704890 0.92 AURKA (0.83) AURKAAURKBGABRA1PLK1PLK4
SCHEMBL2704222 0.91 AURKA (0.85) AURKAAURKBGABRA1PLK1PLK4
SCHEMBL2705102 0.91 AURKA (0.84) AURKAAURKBGABRA1PLK1PLK4
SCHEMBL2705466 0.89 AURKA (0.81) AURKAAURKBGABRA1PLK1PLK4
SCHEMBL26005096 0.89 AURKA (0.84) AURKAAURKBGABRA1PLK1PLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240083906-A1 COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION MILLENNIUM PHARM INC (US) 2024-03-14 US disclosed
US-20220041605-A1 COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION MILLENNIUM PHARMACEUTICALS, INC. 2022-02-10 US disclosed
US-11014928-B2 Compounds and methods for inhibiting mitotic progression MILLENNIUM PHARMACEUTICALS, INC. (US) 2021-05-25 US disclosed
US-11014928-B2 Compounds and methods for inhibiting mitotic progression MILLENNIUM PHARMACEUTICALS, INC. (US) 2021-05-25 US disclosed
EP-2713727-B1 COMBINATION OF MEK INHIBITORS AND SELECTIVE INHIBITORS OF AURORA A KINASE MILLENNIUM PHARM INC (US) 2021-03-31 EP disclosed
EP-3317427-B1 BIOMARKERS OF RESPONSE TO SELECTIVE INHIBITORS OF AURORA A KINASE MILLENNIUM PHARM INC (US) 2020-12-23 EP disclosed
EP-2976086-B1 COMBINATION OF CATALYTIC MTORC 1/2 INHIBITORS AND SELECTIVE INHIBITORS OF AURORA A KINASE MILLENNIUM PHARM INC (US) 2020-10-14 EP disclosed
US-20200247810-A1 COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION MILLENNIUM PHARMACEUTICALS, INC. 2020-08-06 US disclosed
US-20200247810-A1 COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION MILLENNIUM PHARMACEUTICALS, INC. 2020-08-06 US disclosed
US-10414770-B2 Compounds and methods for inhibiting mitotic progression MILLENNIUM PHARMACEUTICALS, INC. (US) 2019-09-17 US disclosed
US-20090299060-A1 COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION MILLENNIUM PHARMACEUTICALS, INC. (US) 2009-12-03 US disclosed
US-7572784-B2 Compounds and methods for inhibiting mitotic progression MILLENNIUM PHARMACEUTICALS, INC. (US) 2009-08-11 US disclosed
US-7572784-B2 Compounds and methods for inhibiting mitotic progression MILLENNIUM PHARMACEUTICALS, INC. (US) 2009-08-11 US disclosed
US-7572784-B2 Compounds and methods for inhibiting mitotic progression MILLENNIUM PHARMACEUTICALS, INC. (US) 2009-08-11 US disclosed
EP-1771450-B9 COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION BY INHIBITION OF AURORA KINASE MILLENNIUM PHARM INC (US) 2008-12-24 EP disclosed
EP-1905773-A2 Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-04-02 EP disclosed
EP-1771450-B1 COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION BY INHIBITION OF AURORA KINASE MILLENNIUM PHARM INC (US) 2007-12-19 EP disclosed
US-20070185087-A1 Compounds and methods for inhibiting mitotic progression MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-08-09 US disclosed
US-20070185087-A1 Compounds and methods for inhibiting mitotic progression MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-08-09 US disclosed
US-20050256102-A1 Compounds and methods for inhibiting mitotic progression MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200247810-A1 COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION AURKC, AURKA, AURKB AURKA 2/4885AURKB 3/4885GABRA1 4822/4885
US-20050256102-A1 Compounds and methods for inhibiting mitotic progression AURKC, AURKA, AURKB AURKA 2/4885AURKB 3/4885GABRA1 4822/4885
US-20070185087-A1 Compounds and methods for inhibiting mitotic progression AURKC, AURKA, AURKB AURKA 2/4885AURKB 3/4885GABRA1 4822/4885
US-10414770-B2 Compounds and methods for inhibiting mitotic progression AURKC, AURKA, AURKB AURKA 2/4885AURKB 3/4885GABRA1 4822/4885
US-11014928-B2 Compounds and methods for inhibiting mitotic progression AURKC, AURKA, AURKB AURKA 2/4885AURKB 3/4885GABRA1 4822/4885
US-20090299060-A1 COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION AURKC, AURKA, AURKB AURKA 2/4885AURKB 3/4885GABRA1 4822/4885
US-20220041605-A1 COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION AURKC, AURKA, AURKB AURKA 2/4885AURKB 3/4885GABRA1 4822/4885
US-20240083906-A1 COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION AURKC, AURKA, AURKB AURKA 2/4885AURKB 3/4885GABRA1 4822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.